Inventiva Appoints New Leaders to Strengthen MASH Drug Development

Inventiva Announced a New Member for the Company

Image Credits: The Pharma Letter

Announcement

Inventiva, a biopharmaceutical company known for the development of oral therapies mainly for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), is happy to experience a transitional shift in the leadership as the company introduces a new president of R&D/ chief medical officer and executive vice president to the company. The company has hired Jason Campagna, MD, phd, as president of research and development and chief medical officer, and Martine Zimmermann, PhD, as executive vice president of regulatory affairs and quality assurance.

About New Members

Dr. Zimmermann will work with the company’s executive leadership team. Recently, she worked for Ipsen as a senior vice president, head of regulatory affairs, where she handled the team that secured regulatory approvals of two liver disease drugs, consisting of Iqirvo, a dual PPARα/ agonist for the treatment of primary biliary cholangitis. Before Ipsen, Dr. Zimmermann was a senior vice president and head of global regulatory affairs and quality at Alexion Pharma, which is also known as AstraZeneca Rare Diseases.

Dr. Campagna will be working with the executive leadership team and introducing new, additional expertise in the MASH. He is a replacement for Pierre Broqua, phd, cofounder and the chief scientific officer, who has been designated as a consultant and scientific advisor, and Michael Cooreman, MD, will be appointed as CMO of the company. Previously, he worked at Q32 Bio as a CMO, and before that, he was a part of the MASH global program and a CMO at Intercept Pharmaceuticals.

Views and Statements

Executive Vice President of Regulatory Affairs and Quality Assurance of Inventiva, Martine Zimmermann, said, “I’m pleased to accept the leadership role during Inventiva’s complex regulatory phase for lanifibranor, which is an excellent pan-PPAR agonist for the treatment of MASH. Throughout my career, I’ve been closely involved in leading global regulatory strategy and approving the compounds for chronic liver disease treatment. Including PPAR in regions like Japan, the US, and Europe. I’m excited to contribute the same my experience to support Lanifibranor.”

MD, PHD, President R&D and CMO of Inventiva, Jason Campagna said, “Inventiva has succeeded in forming a strong scientific and clinical foundation. I’m excited to be a part of this team at this stage, as we have been working towards advancing the lanifibranor to receive approval. The execution and design of my previously led advanced clinical programs at Intercept, also its first ever NDA submission to a similar indication, have gained me experience and understanding of the need and urgency of the therapies to treat MASH patients.”